Details for New Drug Application (NDA): 079188
✉ Email this page to a colleague
NDA 079188 describes EMTRICITABINE, which is a drug marketed by Aurobindo Pharma Ltd, Cipla, Hetero Labs Ltd Iii, Amneal Pharms Co, Apotex, Aurobindo Pharma, Chartwell Rx, Laurus, Macleods Pharms Ltd, Mylan, Strides Pharma, Teva Pharms Usa, and Zydus Pharms, and is included in fifteen NDAs. It is available from three suppliers. Additional details are available on the EMTRICITABINE profile page.
The generic ingredient in EMTRICITABINE is emtricitabine; tenofovir disoproxil fumarate. There are eighteen drug master file entries for this compound. Twenty-nine suppliers are listed for this compound. Additional details are available on the emtricitabine; tenofovir disoproxil fumarate profile page.
The generic ingredient in EMTRICITABINE is emtricitabine; tenofovir disoproxil fumarate. There are eighteen drug master file entries for this compound. Twenty-nine suppliers are listed for this compound. Additional details are available on the emtricitabine; tenofovir disoproxil fumarate profile page.
Summary for 079188
| Tradename: | EMTRICITABINE |
| Applicant: | Aurobindo Pharma Ltd |
| Ingredient: | emtricitabine |
| Patents: | 0 |
| Formulation / Manufacturing: | see details |
Pharmacology for NDA: 079188
| Mechanism of Action | Nucleoside Reverse Transcriptase Inhibitors |
Medical Subject Heading (MeSH) Categories for 079188
Suppliers and Packaging for NDA: 079188
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| EMTRICITABINE | emtricitabine | CAPSULE;ORAL | 079188 | ANDA | Aurobindo Pharma Limited | 65862-301 | 65862-301-05 | 500 CAPSULE in 1 BOTTLE (65862-301-05) |
| EMTRICITABINE | emtricitabine | CAPSULE;ORAL | 079188 | ANDA | Aurobindo Pharma Limited | 65862-301 | 65862-301-30 | 30 CAPSULE in 1 BOTTLE (65862-301-30) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE;ORAL | Strength | 200MG | ||||
| Approval Date: | Mar 15, 2023 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
